AstraZeneca (LSE: AZN) and development partner Merck & Co (NYSE: MRK) have secured a positive reimbursement decision for Lynparza (olaparib) in the UK.
The recommendation relates to a combination therapy, with bevacizumab, for first-line treatment of certain women with advanced ovarian cancer.
Bevacizumab, a type of targeted therapy called an angiogenesis inhibitor, was developed by Roche (ROG: SIX) subsidiary Genentech and sold under the Avastin brand.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze